[Acipimox treatment of hyperlipidemia type II].
The hypolipidemic effect of acipimox, a new inhibitor of lipolysis, was investigated in a double blind crossover trial versus placebo. The trial showed an appreciable and significant reduction in total cholesterol (-14%) and of LDL cholesterol (-20%), a slight but significant increase in HDL cholesterol (+6%), and only a slight diminution of triglycerides and VLDL cholesterol.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011719:Pyrazines / Q000008:administration & dosage*
D000960:Hypolipidemic Agents; D010919:Placebos; D011719:Pyrazines; C027696:acipimox
Behandlung der Hyperlipidämie Typ II mit Acipimox.